Evidence map›Paper›PMID 26248472›Full record

ArticlePediatric nephrology (Berlin, Germany)2015

Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study.

Danielle Carvalho Pedrosa, Fernanda Macedo de Oliveira Neves, Gdayllon Cavalcante Meneses, Gabriela Pinheiro Gomes Wirtzbiki, Carlos Artur da Costa Moraes, Alice Maria Costa Martins, Alexandre Braga Libório

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Danielle Carvalho PedrosaMedical Sciences Post-graduate Program, Department of Clinical Medicine, Universidade Federal do Ceará, Avenue Abolição, 4043, Fortaleza, Ceará, Brazil.
Fernanda Macedo de Oliveira NevesMedical Sciences Post-graduate Program, Department of Clinical Medicine, Universidade Federal do Ceará, Avenue Abolição, 4043, Fortaleza, Ceará, Brazil.
Gdayllon Cavalcante MenesesDepartment of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Ceara, Fortaleza, Ceara, Brazil.
Gabriela Pinheiro Gomes WirtzbikiHospital Infantil Albert Sabin, Fortaleza, Ceará, Brazil.
Carlos Artur da Costa MoraesHospital Infantil Albert Sabin, Fortaleza, Ceará, Brazil.
Alice Maria Costa MartinsDepartment of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Ceara, Fortaleza, Ceara, Brazil.
Alexandre Braga LibórioDepartment of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Ceara, Fortaleza, Ceara, Brazil. alexandreliborio@yahoo.com.br.
Universidade Federal do Ceará · BRHospital Infantil Albert Sabin · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is a significant complication in patients with cancer, and nephrotoxic drugs are among the most common causes of AKI. To date, there is no study evaluating the potential role of renal biomarkers in children receiving nephrotoxic chemotherapy.

methodsA prospective study was conducted in children receiving methotrexate (MTX) or platinum-based treatment. Urinary kidney injury molecule-1 (KIM-1) was measured 24 h after the initiation of the chemotherapy infusion, and serum creatinine (sCr) was measured prior to drug infusion and at 24, 48, 72, and 96 h, 1 and 2 weeks, and 3 months post-initiation of treatment.

resultsA total of 64 children were evaluated, of whom 21 (32.8%) developed AKI. The majority had AKI stage 1 (n = 12, 57.1%) and only one developed AKI stage 3. Median values of urinary KIM-1 were higher in patients with AKI than in those without AKI [10.7, interquartile range (IQR) 1.6-17.9 vs. 4.3 (IQR 1.3-6.1) ng/mg creatinine; p < 0.01]. Urinary KIM-1 showed good discrimination for AKI in patients receiving nephrotoxic chemotherapy, with an area under the receiver operator characteristic curve for AKI up to 1 week later of 0.82 (95% confidence interval 0.66-0.95). Even when measured only 24 h after drug infusion, urinary KIM-1 still showed good discrimination to predict persistent renal impairment three months later.

conclusionUrinary KIM-1 measured 24 h after the start of drug infusion has the potential to detect early AKI in pediatric patients treated with MTX or platinum-class drugs.

Indexed as

Acute Kidney InjuryAntineoplastic AgentsBiomarkersChildChild, PreschoolCohort StudiesFemaleHepatitis A Virus Cellular Receptor 1HumansKidneyKidney Function TestsMaleMembrane GlycoproteinsMethotrexatePlatinum CompoundsProspective StudiesAntineoplastic AgentsBiomarkersHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Membrane GlycoproteinsMethotrexatePlatinum CompoundsReceptors, VirusAcute kidney injuryBiomarkersDiagnostic capacityMethotrexateNephrotoxic chemotherapyPlatinum-class drugsUrinary kidney injury molecule-1

Identifiers

PMID26248472
OpenAlexW2152202809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.